EFSA Deems Extended Use of Bacillolysin Enzyme Safe
EFSA’s experts have evaluated a food enzyme called bacillolysin produced by a non-GM strain of Bacillus amyloliquefaciens (strain AGS 430) and found no safety concerns for its wider use . Previously, this enzyme was considered safe in 11 food manufacturing processes; the applicant sought to extend its use to one additional process . In an updated opinion issued on August 27, 2025, EFSA concluded that even with use in a total of 12 processes, the enzyme’s exposure levels (up to 7.111 mg/kg body weight per day in a worst-case scenario) pose no risk to consumers under the intended conditions . The evaluation also noted that in two processes the enzyme is removed from the final food, and in the remaining uses the dietary exposure is low . Overall, EFSA’s assessment supports the safe expansion of bacillolysin’s use in food production.
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
TSMC, Samsung, and SK Hynix Scramble for Electronic-Grade Hydrofluoric Acid as High-End Supply Tightens; Some Suppliers Raise Prices by 30% This Year
-
“Amputation or Strategic Retreat?”: Shell’s Six-Year Chemical Losses and the Quiet Unwinding of an Empire
-
Tinci Materials Calls Off 2.65 Billion Yuan Project as Electrolyte Giant Shifts Strategy
-
“The 40-Year Ethylene Giant Collapses”: ExxonMobil’s Premature Shutdown Is Not Just Scotland’s Tragedy—It’s the Twilight Elegy of European Industrial Civilization
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
U.S.-Iran Détente Triggers Oil Price Plunge, Energy and Chemical Sectors Tumble
-
Sulfur Price Hits 7,633 CNY/Ton, Up Nearly Sixfold in a Year and a Half; Domestic Refining Giants Halt New Orders Due to Tight Supply
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
Recommend Reading
-
Saudi Aramco Weighs Discounts of Up to $9/Barrel on Oman STS Crude as Freight Costs Surge
-
Europe Faces 510,000-BPD Q4 Jet Fuel Deficit as ARA Stocks Hit Seven-Year Low
-
Crude Oil Tops $100, Asian Propylene Plants Undergo Concentrated Maintenance
-
From Coffee Waste to Superfood Additive: EU Declares Pectin-Rich Arabica Extract Safe for Food Use
-
Australia Approves Lab-Grown “Milk Sugar” for Babies—A Breakthrough in Infant Nutrition
-
Business Society September 21, 2026 PTA Trend Analysis: Clear Downtrend
-
Premium Global Chemical Sourcing Requests (17-20Sep.,2026)
-
Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy
-
Escalating Conflict Drives Up Risk Premium; Crude Oil Hits New High in Over a Month
-
China's Natural Rubber Market Fluctuates with an Initial Rise Followed by a Fall, Experiencing Range-bound Volatility